Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | AKT2 | P31751 | 3/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | TLK2 | Q86UE8 | 4/20 | 0.42 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.41 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.41 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 3/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3572328 | 1.00 | PDPK1 (0.46) | PDPK1AKT2RAF1TLK2CDYL2 | |
| SCHEMBL3581636 | 0.94 | PDPK1 (0.43) | PDPK1AKT2RAF1TLK2JAK3 | |
| SCHEMBL3570002 | 0.93 | AKT2 (0.39) | PDPK1AKT2RAF1TLK2CDYL2 | |
| SCHEMBL3572331 | 0.91 | LMNA (0.45) | PDPK1RAF1TLK2CDYL2CDYL | |
| SCHEMBL4758177 | 0.89 | CDYL2 (0.44) | PDPK1AKT2RAF1TLK2CDYL2 | |
| SCHEMBL3581378 | 0.89 | CDYL2 (0.44) | PDPK1AKT2RAF1TLK2CDYL2 | |
| SCHEMBL3581640 | 0.88 | RAF1 (0.42) | RAF1TLK2JAK3GSK3BNTRK1 | |
| SCHEMBL3584594 | 0.87 | PDPK1 (0.48) | PDPK1AKT2RAF1TLK2CDYL2 | |
| SCHEMBL3578279 | 0.87 | TGM2 (0.37) | PDPK1RAF1TLK2LMNAMAPT | |
| SCHEMBL3579184 | 0.87 | AKT2 (0.44) | PDPK1AKT2CDYL2CDYLCDY1; CDY1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | claimed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | PDPK1 86/4885AKT2 168/4885RAF1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.